Credit: Shutterstock photoLantheus Holdings, which sells medical imaging agents used in the diagnosis of cardiovascular diseases, announced terms for its IPO on Tuesday.
The North Billerica, MA-based company plans to raise $75 million by offering 7.9 million shares at a price range of $8.50 to $10.50. At the midpoint of the proposed range, it would command a market value of $251 million.
In July 2014, Lantheus had planned to raise $125 million at a market cap of $370 million, but postponed the IPO.
Lantheus Holdings, which was founded in 1956 and booked $303 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol LNTH. Credit Suisse, Jefferies, RBC Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of June 22, 2015.
The article Diagnostics company Lantheus revives IPO plans and sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
